Durvalumab after chemo-radiotherapy in stage III non-small cell lung cancer.
Affiliation
Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UKIssue Date
2018-04
Metadata
Show full item recordCitation
Durvalumab after chemo-radiotherapy in stage III non-small cell lung cancer. 2018, 10(Suppl 9): S991-S994 J Thorac DisJournal
Journal of Thoracic DiseaseDOI
10.21037/jtd.2018.04.29PubMed ID
29850180Type
ArticleLanguage
enISSN
2072-1439ae974a485f413a2113503eed53cd6c53
10.21037/jtd.2018.04.29
Scopus Count
Collections
Related articles
- Patients with unresectable stage III non-small cell lung cancer eligible to receive consolidation therapy with durvalumab in clinical practice based on PACIFIC study criteria.
- Authors: Sakaguchi T, Ito K, Furuhashi K, Nakamura Y, Suzuki Y, Nishii Y, Taguchi O, Hataji O
- Issue date: 2019 Sep
- Immune checkpoint-inhibitors and chemoradiation in stage III unresectable non-small cell lung cancer.
- Authors: Melosky B, Juergens R, McLeod D, Leighl N, Brade A, Card PB, Chu Q
- Issue date: 2019 Aug
- Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study.
- Authors: Hui R, Özgüroğlu M, Villegas A, Daniel D, Vicente D, Murakami S, Yokoi T, Chiappori A, Lee KH, de Wit M, Cho BC, Gray JE, Rydén A, Viviers L, Poole L, Zhang Y, Dennis PA, Antonia SJ
- Issue date: 2019 Dec
- Durvalumab: a potential maintenance therapy in surgery-ineligible non-small-cell lung cancer.
- Authors: Shafique MR, Robinson LA, Antonia S
- Issue date: 2018
- Sequential versus concurrent chemo-radiotherapy in inoperable stage III non-small cell lung cancer.
- Authors: El-Sharouni SY, Kal HB, Battermann JJ, Schramel FM
- Issue date: 2006 Jan-Feb